BACKGROUND AND PURPOSE: Meningiomas are the most common primary intracranial tumors, typically treated with surgery and adjuvant radiation in cases of subtotal resection and/or higher histopathologic grade. Contrast-enhanced magnetic resonance imaging (MRI) is the gold standard for postoperative assessment and adjuvant treatment planning. However, MRI can have limited accuracy particularly in the presence of posttreatment change. [68Ga]-DOTATATE is a Positron Emission Tomography (PET) radiotracer targeting somatostatin receptor 2A (SSTR2A). SSTR2A is a reliable biomarker of meningiomas. We report a consecutive case series of 20 patients evaluated with [68Ga]-DOTATATE PET/MRI, propose a novel approach to quantitative analysis, and discuss clinical implications. METHODS: We present a consecutive case series of 20 patients with clinically suspected or pathology-proven meningioma evaluated between July 2018 and February 2019. [68Ga]-DOTATATE PET/MRI was obtained in order to confirm the diagnosis or determine tumor recurrence/progression to help guide surgical and/or radiation therapy management in cases in which MRI findings were indeterminate or equivocal. RESULTS: Seventeen (85%) patients had undergone prior surgery and 11 (55%) underwent adjuvant radiation therapy. In 17 patients [68Ga]-DOTATATE confirmed the presence of recurrent meningioma. A total of 49 meningiomas were identified (median: 2 meningiomas/patient, range 0-14). There was excellent differentiation between meningioma and posttreatment change based on our approach of target lesion/superior sagittal sinus maximum standardized uptake values ratio (16.6 vs. 1.6, P < .0001). CONCLUSIONS: [68Ga]-DOTATATE PET/MRI is a promising tool in the assessment of both treatment naïve and resected/irradiated meningiomas, allowing improved diagnosis and extent of disease evaluation. Future prospective studies are needed to determine utility of [68Ga]-DOTATATE PET/MRI in treatment response assessment.
BACKGROUND AND PURPOSE:Meningiomas are the most common primary intracranial tumors, typically treated with surgery and adjuvant radiation in cases of subtotal resection and/or higher histopathologic grade. Contrast-enhanced magnetic resonance imaging (MRI) is the gold standard for postoperative assessment and adjuvant treatment planning. However, MRI can have limited accuracy particularly in the presence of posttreatment change. [68Ga]-DOTATATE is a Positron Emission Tomography (PET) radiotracer targeting somatostatin receptor 2A (SSTR2A). SSTR2A is a reliable biomarker of meningiomas. We report a consecutive case series of 20 patients evaluated with [68Ga]-DOTATATE PET/MRI, propose a novel approach to quantitative analysis, and discuss clinical implications. METHODS: We present a consecutive case series of 20 patients with clinically suspected or pathology-proven meningioma evaluated between July 2018 and February 2019. [68Ga]-DOTATATE PET/MRI was obtained in order to confirm the diagnosis or determine tumor recurrence/progression to help guide surgical and/or radiation therapy management in cases in which MRI findings were indeterminate or equivocal. RESULTS: Seventeen (85%) patients had undergone prior surgery and 11 (55%) underwent adjuvant radiation therapy. In 17 patients [68Ga]-DOTATATE confirmed the presence of recurrent meningioma. A total of 49 meningiomas were identified (median: 2 meningiomas/patient, range 0-14). There was excellent differentiation between meningioma and posttreatment change based on our approach of target lesion/superior sagittal sinus maximum standardized uptake values ratio (16.6 vs. 1.6, P < .0001). CONCLUSIONS: [68Ga]-DOTATATE PET/MRI is a promising tool in the assessment of both treatment naïve and resected/irradiated meningiomas, allowing improved diagnosis and extent of disease evaluation. Future prospective studies are needed to determine utility of [68Ga]-DOTATATE PET/MRI in treatment response assessment.
Authors: Keenan Piper; Siyuan Yu; Mohammad Taghvaei; Christian Fernandez; Nikolaos Mouchtouris; Rupert D Smit; Clifford Yudkoff; Sarah Collopy; Maikerly Reyes; Pascal Lavergne; Michael Karsy; Giyarpuram N Prashant; Wenyin Shi; James Evans Journal: Front Surg Date: 2022-07-04
Authors: Jana Ivanidze; Michelle Roytman; Myrto Skafida; Sean Kim; Shannon Glynn; Joseph R Osborne; Susan C Pannullo; Sadek Nehmeh; Rohan Ramakrishna; Theodore H Schwartz; Jonathan P S Knisely; Eaton Lin; Nicolas A Karakatsanis Journal: Radiol Imaging Cancer Date: 2022-03
Authors: Frank A E Kruyt; Rob J M Groen; Bianca M Dijkstra; Marion de Jong; Marcus C M Stroet; Fritz Andreae; Sebastiaan E Dulfer; Marieke Everts; Schelto Kruijff; Julie Nonnekens; Wilfred F A den Dunnen Journal: J Neurooncol Date: 2021-03-26 Impact factor: 4.130
Authors: Sean S Mahase; Diana A Roth O'Brien; Diana No; Michelle Roytman; Myrto E Skafida; Eaton Lin; Nicolas A Karakatsanis; Joseph R Osborne; Andrew Brandmaier; Susan C Pannullo; Rohan Ramakrishna; Philip E Stieg; Jonathan P S Knisely; Jana Ivanidze Journal: Neurooncol Adv Date: 2021-01-21
Authors: Roland Goldbrunner; Pantelis Stavrinou; Michael D Jenkinson; Felix Sahm; Christian Mawrin; Damien C Weber; Matthias Preusser; Giuseppe Minniti; Morten Lund-Johansen; Florence Lefranc; Emanuel Houdart; Kita Sallabanda; Emilie Le Rhun; David Nieuwenhuizen; Ghazaleh Tabatabai; Riccardo Soffietti; Michael Weller Journal: Neuro Oncol Date: 2021-11-02 Impact factor: 13.029
Authors: Peter C Pan; David J Pisapia; Rohan Ramakrishna; Theodore H Schwartz; Susan C Pannullo; Jonathan P S Knisely; Gloria C Chiang; Jana Ivanidze; Philip E Stieg; Benjamin Liechty; Andrew Brandmaier; Howard A Fine; Rajiv S Magge Journal: Neurooncol Adv Date: 2021-06-29